Cargando…

Validation of Death and Dying Distress Scale-Chinese Version and Prevalence of Death Anxiety Among Patients With Advanced Cancer

Purpose: Death anxiety is commonly experienced by individuals with advanced cancer who have a limited life expectancy. The Death and Dying Distress Scale (DADDS) is a validated measure that was created to capture this experience; but no Chinese version is available to date. We conducted a cross-sect...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Lili, Zhang, Yening, Pang, Ying, Zhou, Yuhe, Li, Jinjiang, Song, Lili, He, Yi, Li, Zimeng, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564352/
https://www.ncbi.nlm.nih.gov/pubmed/34744816
http://dx.doi.org/10.3389/fpsyt.2021.715756
_version_ 1784593599735791616
author Tang, Lili
Zhang, Yening
Pang, Ying
Zhou, Yuhe
Li, Jinjiang
Song, Lili
He, Yi
Li, Zimeng
Wang, Yan
author_facet Tang, Lili
Zhang, Yening
Pang, Ying
Zhou, Yuhe
Li, Jinjiang
Song, Lili
He, Yi
Li, Zimeng
Wang, Yan
author_sort Tang, Lili
collection PubMed
description Purpose: Death anxiety is commonly experienced by individuals with advanced cancer who have a limited life expectancy. The Death and Dying Distress Scale (DADDS) is a validated measure that was created to capture this experience; but no Chinese version is available to date. We conducted a cross-sectional study to explore the psychometric properties of a Chinese version DADDS (DADDS-C) and address prevalence of death anxiety among patients with advanced cancer. Methods: Patients with advanced cancer were recruited from Peking University Cancer Hospital. Measures administered included: DADDS-C, Patient Health Questionnaire (PHQ-9), General Anxiety Disorder-7(GAD-7), Quality of Life at End of Life in Cancer (QUAL-EC), Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-sp). McDonald's Omega, Cronbach's alpha, Exploratory Factor Analysis and Confirmatory Factor Analysis were used to test DADDS-C's reliability and validity. Logistic regression analysis was used to identify risk factors for death anxiety. Results: Of 300 patients approached, 256 (85%) provided informed consent and completed the questionnaires. Of these participants, 43 (16.8%) had moderate death anxiety based on scores of ≥45 on the DADDS-C. Three factors (feeling shortness of time, dying and death distress, being a burden to others) explained 71.643% of shared variation with factor loadings ranging from 0.629 to 0.822. Cronbach's alpha was 0.939; Omega total was 0.959. DADDS-C had acceptable convergent and discriminant validity. Logistic regression analysis indicated that two factors (better relationship with healthcare providers and preparation for end of life) protected patients from death anxiety. Conclusion: DADDS-C is a valid tool for measuring death anxiety in Chinese patients with advanced cancer. The presence of at least moderate death anxiety in a substantial minority of these patients calls for screening for this symptom and for more routine psychological interventions to alleviate and prevent such distress in this population.
format Online
Article
Text
id pubmed-8564352
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85643522021-11-04 Validation of Death and Dying Distress Scale-Chinese Version and Prevalence of Death Anxiety Among Patients With Advanced Cancer Tang, Lili Zhang, Yening Pang, Ying Zhou, Yuhe Li, Jinjiang Song, Lili He, Yi Li, Zimeng Wang, Yan Front Psychiatry Psychiatry Purpose: Death anxiety is commonly experienced by individuals with advanced cancer who have a limited life expectancy. The Death and Dying Distress Scale (DADDS) is a validated measure that was created to capture this experience; but no Chinese version is available to date. We conducted a cross-sectional study to explore the psychometric properties of a Chinese version DADDS (DADDS-C) and address prevalence of death anxiety among patients with advanced cancer. Methods: Patients with advanced cancer were recruited from Peking University Cancer Hospital. Measures administered included: DADDS-C, Patient Health Questionnaire (PHQ-9), General Anxiety Disorder-7(GAD-7), Quality of Life at End of Life in Cancer (QUAL-EC), Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-sp). McDonald's Omega, Cronbach's alpha, Exploratory Factor Analysis and Confirmatory Factor Analysis were used to test DADDS-C's reliability and validity. Logistic regression analysis was used to identify risk factors for death anxiety. Results: Of 300 patients approached, 256 (85%) provided informed consent and completed the questionnaires. Of these participants, 43 (16.8%) had moderate death anxiety based on scores of ≥45 on the DADDS-C. Three factors (feeling shortness of time, dying and death distress, being a burden to others) explained 71.643% of shared variation with factor loadings ranging from 0.629 to 0.822. Cronbach's alpha was 0.939; Omega total was 0.959. DADDS-C had acceptable convergent and discriminant validity. Logistic regression analysis indicated that two factors (better relationship with healthcare providers and preparation for end of life) protected patients from death anxiety. Conclusion: DADDS-C is a valid tool for measuring death anxiety in Chinese patients with advanced cancer. The presence of at least moderate death anxiety in a substantial minority of these patients calls for screening for this symptom and for more routine psychological interventions to alleviate and prevent such distress in this population. Frontiers Media S.A. 2021-10-20 /pmc/articles/PMC8564352/ /pubmed/34744816 http://dx.doi.org/10.3389/fpsyt.2021.715756 Text en Copyright © 2021 Tang, Zhang, Pang, Zhou, Li, Song, He, Li and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Tang, Lili
Zhang, Yening
Pang, Ying
Zhou, Yuhe
Li, Jinjiang
Song, Lili
He, Yi
Li, Zimeng
Wang, Yan
Validation of Death and Dying Distress Scale-Chinese Version and Prevalence of Death Anxiety Among Patients With Advanced Cancer
title Validation of Death and Dying Distress Scale-Chinese Version and Prevalence of Death Anxiety Among Patients With Advanced Cancer
title_full Validation of Death and Dying Distress Scale-Chinese Version and Prevalence of Death Anxiety Among Patients With Advanced Cancer
title_fullStr Validation of Death and Dying Distress Scale-Chinese Version and Prevalence of Death Anxiety Among Patients With Advanced Cancer
title_full_unstemmed Validation of Death and Dying Distress Scale-Chinese Version and Prevalence of Death Anxiety Among Patients With Advanced Cancer
title_short Validation of Death and Dying Distress Scale-Chinese Version and Prevalence of Death Anxiety Among Patients With Advanced Cancer
title_sort validation of death and dying distress scale-chinese version and prevalence of death anxiety among patients with advanced cancer
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564352/
https://www.ncbi.nlm.nih.gov/pubmed/34744816
http://dx.doi.org/10.3389/fpsyt.2021.715756
work_keys_str_mv AT tanglili validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer
AT zhangyening validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer
AT pangying validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer
AT zhouyuhe validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer
AT lijinjiang validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer
AT songlili validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer
AT heyi validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer
AT lizimeng validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer
AT wangyan validationofdeathanddyingdistressscalechineseversionandprevalenceofdeathanxietyamongpatientswithadvancedcancer